Candel Therapeutics to present NSCLC aglatimagene besadenovec study data at SITC 2026

Bitget2026/10/02 13:00

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Candel Therapeutics set two poster presentations at SITC’s 41st Annual Meeting, November 4-8, 2026 in Phoenix.
Results will be presented in the future, not previously disclosed in this announcement.
NSCLC poster highlights analyses linking aglatimagene besadenovec with immune activation tied to improved survival after checkpoint inhibitor failure.
Recurrent glioblastoma poster outlines phase 1b findings supporting linoserpaturev combined with VEGF blockade to counter tumor-driven immune suppression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838084) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Candel Therapeutics to present NSCLC aglatimagene besadenovec study data at SITC 2026

You may also like

Crypto prices